Core Insights - Suning Universal is focusing on a dual business strategy of real estate and medical aesthetics, aiming for collaborative development in both sectors [3] Group 1: Investor Relations Activity - The investor relations activity took place on September 17, 2025, in Nanjing, with participation from 20 institutions including Guotai Junan Securities and Guosheng Securities [2] - Key personnel from Suning Universal included Vice President Jiang Libo, Financial Head Liu Debo, and Medical Aesthetics Group's Ma Guoyi [2] Group 2: Business Development Strategy - Suning Universal is committed to its dual business strategy, emphasizing real estate development and sales while expanding into the medical aesthetics sector [3] - The real estate business is well-established, particularly in the Yangtze River Delta region, with a total land reserve of over 1.55 million square meters, primarily in economically developed areas [3] - The company has a low debt ratio of 29.74% as of mid-2025, indicating strong financial health [3] Group 3: Medical Aesthetics Sector - The medical aesthetics segment has seen significant investment, with seven operational medical aesthetics institutions, including the recently opened Suya Medical Aesthetics in Wuxi [3] - In the first half of 2025, pre-sales in the medical aesthetics sector reached 92.829 million yuan, marking an 18% year-on-year increase [3] - Future plans include expanding the medical aesthetics business through new store openings, acquisitions, and optimizing the supply chain to reduce costs [3] Group 4: Shareholder Returns - Suning Universal has a history of cash dividends, with a total of 966 million yuan distributed since 2022, and plans to continue rewarding shareholders through stable performance and growth [3]

Group 1: Company Overview - Suning Universal Co., Ltd. focuses on real estate development and sales, pursuing a dual business strategy in real estate and medical aesthetics [2][3] - The company adheres to a "low debt, high return" operational strategy, emphasizing sustainable development [3] Group 2: Real Estate Business Performance - In 2025, the real estate sector remains under pressure, but the company has over 30 years of experience, enabling strong strategic decision-making [3] - The total land reserve is approximately 155 million square meters, primarily located in economically developed areas of the Yangtze River Delta, providing a significant competitive advantage [3] - The company's asset-liability ratio is 29.74%, with a net asset-liability ratio of 27.43%, indicating a solid financial foundation [5] Group 3: Medical Aesthetics Business - The company has established 7 medical aesthetics institutions, with the new Wuxi Suya Medical Aesthetics center already in trial operation [3][4] - In the first half of 2025, pre-receipts for Suya Medical Aesthetics reached 92.829 million yuan, a year-on-year increase of 18% [3] Group 4: Future Development Plans - The company plans to expand its medical aesthetics business through self-built stores and acquisitions, focusing on biomedicine and anti-aging [4] - By 2026, the revenue share from the medical aesthetics sector is expected to significantly increase as new institutions become operational [4] Group 5: Shareholder Returns - The company has consistently prioritized shareholder returns, with total cash dividends amounting to 966 million yuan since 2022, maintaining a high dividend yield [6] Group 6: Strategic Outlook - The company aims to drive growth through its dual business model, leveraging stable cash flow from real estate to expand medical aesthetics revenue [7] - There is an ongoing focus on high-tech industries and new business opportunities to optimize the company's operational structure [7]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025, indicating challenges in its operational performance while maintaining a healthy financial structure with a low debt ratio [2][5][12] Financial Performance - The company's operating revenue for the first half of 2025 was 933.64 million yuan, a decrease of 28.67% compared to the same period last year [2][5] - The net profit attributable to shareholders was 137.31 million yuan, down 45.51% year-on-year [2][5] - The net profit after deducting non-recurring gains and losses was also negative, with a cash flow from operating activities of -62.58 million yuan, a decline of 127.65% [2][5] Key Business Developments - The company focused on real estate and medical beauty as its dual main businesses, optimizing resource allocation and promoting multi-business synergy [6][10] - In the real estate sector, the company concentrated resources in the Yangtze River Delta region, enhancing product competitiveness through refined space planning and a comprehensive product system [6][10] - The company successfully launched key projects, such as the Nanjing Rongjin Ruifu, which received positive market feedback and achieved early high-quality delivery [6][7] Sales and Marketing Strategies - The company implemented targeted sales strategies, including limited-time discounts and promotional offers, to stimulate demand and accelerate sales recovery [7][8] - The sales performance of residential projects like Nanjing Rongjin Ruifu and Binjiang Yayuan was strong, with commercial project sales in cities like Nanjing and Wuxi seeing a 100.47% increase year-on-year [7][8] Medical Beauty Sector Growth - The medical beauty segment achieved significant growth, with total service visits reaching 78,273, an increase of 11.4%, and consumption visits at 39,862, up 18.1% [8][10] - The company’s medical beauty brand, Suya Medical Beauty, received multiple awards, enhancing its market reputation and customer satisfaction [8][10] Financial Health and Risk Management - The company maintained a low debt ratio of 29.74%, indicating a healthy financial structure and manageable debt risks [12] - The company emphasized risk management and compliance, implementing regular risk assessments and enhancing internal controls to ensure sustainable development [9][12]

Group 1: Medical Aesthetics Business Development - The company plans to increase investment in the medical aesthetics sector, aiming to enhance the market recognition and reputation of the Suya Medical Aesthetics brand. In 2025, new medical aesthetics institutions are planned to open in Jiangsu and Shanghai [2][3] - In 2024, the medical aesthetics segment achieved revenue of 179 million yuan and is currently profitable. The company will continue to focus on self-built facilities and expand in high-consumption areas like the Yangtze River Delta [5][6] Group 2: Shareholder Engagement and Stock Performance - In 2024, the actual controller and some executives completed a round of share buybacks, demonstrating confidence in the company's long-term investment value [3][4] - The company is committed to a "long-termism" approach, focusing on stable operations and long-term value creation, despite current market pressures affecting stock prices [4][6] Group 3: Strategic Business Direction - The company is dedicated to developing medical aesthetics and biopharmaceuticals, emphasizing a long-term strategy and resource optimization to enhance operational efficiency and profitability [3][5] - Future business expansion will include exploring new industries and opportunities, with a focus on maintaining a balanced approach to growth and avoiding reckless expansion [5][6] Group 4: Market Conditions and Company Response - The company's stock price has been under pressure due to macroeconomic factors, industry developments, and investor expectations. The company aims to improve product quality, brand building, and customer service to enhance overall competitiveness [6][7] - New medical aesthetics facilities are under construction, with plans for trial operations expected around mid-year [6][7]